Opthea (OPT) Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025 summary

Key clinical developments

• Sozinibercept, a VEGF-C/D trap inhibitor, is in Phase 3 for wet AMD, aiming to improve vision outcomes when combined with anti-VEGF-A agents.

• Top-line Phase 3 COAST trial results (aflibercept + Sozinibercept) are expected early Q2, with ShORe (ranibizumab + Sozinibercept) readout mid-year.

• Phase 2b showed statistical superiority in vision gains and safety for Sozinibercept combinations versus standard of care.

• Pivotal trials are large, global, and designed to support a broad label for use with any anti-VEGF-A therapy.

• Final BLA module submission is guided for early 2026, with potential FDA approval by end of 2026 due to Fast Track status.

Market and competitive positioning

• Sozinibercept is the only emerging agent in wet AMD focused on vision improvement, addressing the highest unmet need.

• No direct competition, as it is designed to complement all anti-VEGF-A drugs, targeting a $12 billion global wet AMD market.

• Market research indicates payers and physicians are receptive to the product if it delivers at least a 20% improvement in visual outcomes.

• Payers are comfortable with pricing in the $1,800–$2,600 per injection range, similar to existing branded anti-VEGF-As.

• U.S. market is highly concentrated, making commercial launch manageable for a biotech company.

Patient and physician perspectives

• Vision preservation is the top priority for patients and retina specialists, with most current therapies failing to restore driving-level vision.

• In Phase 2b, 42% more patients in the combination arm retained driving ability compared to monotherapy.

• Physicians indicate 24–41% of their patients would benefit from the drug, depending on the degree of vision improvement.

• Two injections in the same eye are already routine in the U.S., reducing barriers to adoption.

• Flexibility in dosing (every 4 or 8 weeks) is important for reimbursement and real-world practice.